Abstract
Objective: Basal insulin analogs, with durations of action sufficient for coverage over the course of 24h, are important for the proper management of glycemic control in diabetic patients. LY2963016 (LY IGlar), an insulin analog has the same amino acid sequence as Lantus® (IGlar). The pharmacological properties of six independent lots of LY IGlar and IGlar were compared using a panel of in vitro biological assays to determine the pharmacological similarity of LY IGlar compared to IGlar.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
